Trillium reports Phase I data for TT-621 in mycosis fungoides

By Allison Johnson | Jan 5, 2018 | 9:51 PM GMT

Trillium Therapeutics Inc. (TSX:TRIL; NASDAQ:TRIL) reported preliminary data from 10 patients with relapsed or refractory mycosis fungoides in the Phase I TTI-621-02